Psychiatric Medication for Teens Ages 15–18: What Careful Prescribing Looks Like
Treatment during the transition to adulthood requires age-specific attention to diagnosis, privacy, family involvement, medication choice, and monitoring.
A 16-year-old is referred for anxiety. Her mother describes falling grades, irritability, and hours spent alone in her room. The patient says she cannot sleep and wants something that will work quickly.
Seen alone, she gives a different account. She has been using cannabis most nights. She sometimes vomits after eating. She has recently gone several nights on very little sleep without feeling tired. Her parents know none of this, and she does not think it has anything to do with the prescription.
It has everything to do with the prescription.
The medication being considered may be familiar. The decision is not. Treating a teenager requires the clinician to understand not only the symptoms but the developmental, family, school, medical, and social setting in which they appeared.
Treating patients beginning at age 15 does not mean applying an adult prescribing model to younger people.
It means using age-specific standards around diagnosis, consent, privacy, medication choice, family involvement, and follow-up. The American Academy of Child and Adolescent Psychiatry recommends that psychiatric medication for young people follow a comprehensive assessment, meaningful participation by the adolescent and family, attention to psychotherapy and other supports, and systematic monitoring.
Medication should sit within a broader treatment plan that may include psychotherapy, school collaboration, attention to sleep and substance use, and work with the family when appropriate.
A teenager is not simply a smaller adult
Between 15 and 18, young people differ greatly in judgment, impulse control, self-awareness, and ability to manage treatment.
One 15-year-old may understand a medication clearly but depend on a parent to obtain, store, and administer it. A 17-year-old may appear completely independent while concealing missed doses, cannabis use, sexual adverse effects, or worsening suicidal thinking.
At 18, most patients gain legal control of their treatment and health information, although their practical ability to manage appointments, refills, insurance problems, and emergencies may still be developing. Federal privacy guidance explains how parental authority generally changes when a patient reaches adulthood, subject to guardianship or another legally recognized authority.
Careful prescribing therefore includes an assessment of what the young person can actually do. Can the patient explain why the medication is being prescribed? Recognize an important adverse effect? Take it consistently? Keep it secure? Ask for help when symptoms worsen?
Growing autonomy matters. So does knowing when the patient still needs adult structure.
The diagnosis comes before the prescription
Adolescent symptoms are often nonspecific.
Inattention may reflect ADHD or anxiety, depression, trauma, cannabis use, a learning problem, or chronic sleep deprivation. Irritability may occur in depression, anxiety, bipolar illness, substance use, family conflict, or ordinary developmental opposition.
A teenager who says, “I can’t sleep” may have insomnia, a delayed sleep schedule, stimulant exposure, intense nighttime device use, or a reduced need for sleep associated with an emerging mood episode.
That is why the evaluation must extend beyond a symptom checklist.
We usually need information from both the adolescent and a parent or guardian. Parents often see changes in attendance, appetite, behavior, hygiene, or school functioning. Adolescents may be the only source for panic, obsessions, hopelessness, trauma, self-harm, substance use, sexual adverse effects, or unusual thoughts and perceptions.
Neither account automatically replaces the other. The difference between them may be clinically important.
A screening score can identify an area that needs attention. It cannot by itself establish the diagnosis, determine the cause, or decide that medication is warranted. Medication should not be started simply because a parent requests it, a questionnaire score is elevated, a therapist suggests it, or another clinician previously assigned a diagnosis.
Parents are involved, but the teenager must be heard
For patients under 18, an authorized parent or guardian ordinarily provides legal consent for medication. The practice must know who has that authority, particularly when parents are divorced, custody is shared, or participation is restricted.
Consent is not the same as the adolescent’s agreement.
The young person should understand what the clinician thinks is happening, what the medication is expected to change, what the alternatives are, what adverse effects matter, and how treatment will be monitored. A teenager who believes medication is being imposed to improve grades, reduce family conflict, or make the patient easier to manage is unlikely to become a reliable partner in treatment.
Every adolescent also needs some private time with the clinician. The American Academy of Pediatrics describes routine time alone as developmentally appropriate and emphasizes that confidentiality supports candor, engagement, and increasing independence. Privacy also has legal and practical limits involving safety, abuse, custody, patient portals, and insurance communications.
Parents need to know what to monitor, how medication will be managed, and what requires an urgent call. They do not need a report of everything the adolescent says privately.
The treatment target must be specific
“Anxiety,” “mood,” “focus,” and “sleep” are too broad to guide treatment. A useful target might be panic attacks occurring several times a week, depression accompanied by withdrawal and school absence, compulsions occupying hours each day, attention problems causing impairment at school and at home, or a clearly defined manic or psychotic condition.
The family should know what improvement would look like and how long a fair trial is expected to take. Symptoms, functioning, and adverse effects should be tracked separately. A patient may feel somewhat less depressed while still missing school, isolating, or remaining unsafe.
We also discuss whether a proposed use is FDA-approved for the patient’s age and condition or is off-label, meaning that an approved medication is being used for an age, condition, or purpose not specifically included in its FDA approval. Off-label prescribing can be appropriate. The reasoning should be explicit.
Antidepressants require an early monitoring plan
Before prescribing an antidepressant, the clinician should look carefully for evidence of bipolar-spectrum illness: periods of unusually reduced need for sleep, marked elevation or irritability, grandiosity, or behavioral disinhibition, an abrupt loss of ordinary restraint that may lead to impulsive, reckless, aggressive, or uncharacteristic behavior.
FDA antidepressant labeling warns of an increased risk of suicidal thinking and behavior in children, adolescents, and young adults during short-term treatment. It calls for close observation for worsening, agitation, irritability, impulsivity, unusual behavioral changes, and suicidality, particularly early in treatment and around dose changes.
This does not mean that adolescents with serious depression should be denied treatment. Untreated depression itself can be dangerous. It means that every prescription should include a clear plan for what the patient and family will watch for and when the clinician will reassess.
Early trouble may not look like sadness. It may appear as abrupt agitation, new impulsivity, severe irritability, markedly reduced sleep, aggression, restlessness, self-harm, or a sudden increase in energy before mood has improved. For example, a previously quiet teenager may suddenly become intensely restless, begin acting without ordinary restraint, and sleep only a few hours without appearing tired.
Sexual adverse effects should be discussed privately. Adolescents may stop taking medication rather than disclose them in front of a parent.
Before increasing an antidepressant, the clinician should determine whether it was taken consistently and for long enough. A missed-dose pattern can look like treatment failure, relapse, or a new illness.
A positive suicide-risk screen also requires direct assessment rather than another questionnaire alone. Current imminent risk calls for urgent safety action. A nonacute positive screen should be followed by a structured safety assessment and a disposition based on the findings. The National Institute of Mental Health provides a youth outpatient framework for conducting that assessment.
ADHD treatment is more than choosing a stimulant
A patient’s ability to concentrate better on a stimulant does not establish an ADHD diagnosis.
The evaluation should demonstrate persistent symptoms, meaningful impairment, and evidence in more than one setting. It should examine sleep, anxiety, depression, trauma, learning problems, substance use, and other conditions that can resemble or complicate ADHD. The American Academy of Pediatrics ADHD guideline emphasizes assessment across settings, consideration of coexisting conditions, adolescent assent, and titration toward the greatest benefit with the fewest adverse effects.
Before medication, we assess height, weight, blood pressure, pulse, appetite, sleep, cardiac history, mood symptoms, substance use, and exposure to caffeine, energy drinks, nicotine, or nonprescribed stimulants.
The treatment must work outside the classroom as well as inside it. A medication that improves concentration but prevents the teenager from eating until evening, delays sleep, worsens anxiety, or produces severe late-day rebound may need to be changed.
Diversion—the sharing, selling, or transfer of prescribed medication to someone for whom it was not prescribed—is a routine clinical issue. Adolescents may be asked to share or sell stimulant medication. Families should know how it will be stored, who has access, and what the policy will be if medication is repeatedly lost or requested early.
Non-stimulant medication may reduce diversion risk, but it is not free of adverse effects. Some non-stimulants can cause sedation, dizziness, low blood pressure, or other clinically important problems and may require gradual discontinuation.
Antipsychotics and mood stabilizers require a higher threshold
Antipsychotic medication can be indispensable when properly indicated. It can also produce weight gain, metabolic changes, sedation, movement symptoms, hormonal effects, and other significant burdens.
“Severe irritability,” “mood swings,” insomnia, or family conflict is not by itself a sufficient reason to prescribe one. The clinician should be able to identify the diagnosis or specific group of symptoms being treated, explain why that particular medication is being used, and state how benefit and adverse effects will be measured.
Baseline assessment may include weight, BMI, blood pressure, glucose or A1c, lipids, movement assessment, and medication-specific studies. Weight and metabolic changes should be followed from the beginning rather than addressed only after they become severe. AACAP recommends systematic monitoring of metabolic measures, vital signs, and movement disorders in young people taking antipsychotic medication.
Akathisia, an intense inner restlessness that may make a patient unable to sit still, deserves particular attention.Patients may describe it as unbearable anxiety. If it is mistaken for worsening psychiatric illness, increasing the dose can make the problem worse.
Mood stabilizers present different issues.
Lithium requires blood-level monitoring and attention to kidney and thyroid function, hydration, illness, salt balance, and interacting medications. Dehydration, vomiting, diarrhea, and heavy sweating can increase toxicity risk, as described in FDA lithium labeling.
Lamotrigine must be increased gradually. Its FDA labeling warns that serious rash is more frequent in pediatric patients and says the medication should ordinarily be discontinued at the first sign of rash unless it is clearly not drug-related. A patient who has stopped it for several days should not simply restart the former dose without guidance.
Valproate carries important hepatic, pancreatic, hematologic, and reproductive risks. FDA prescribing information emphasizes major fetal risks and the need for particular caution when treating anyone who could become pregnant.
These medications should not be prescribed merely because a teenager is described as “moody.”
Sleep problems should not automatically produce another medication
Teenagers commonly sleep at biologically and socially inconvenient times. School schedules, late-night device use, anxiety, depression, stimulants, cannabis, caffeine, and different routines in two households can all contribute.
Before adding a sleep medication, the clinician should establish what is keeping the patient awake.
A medication that produces sleep but causes morning sedation, impaired driving, school absence, or cognitive dulling has not solved the larger problem. Sedatives also require attention to alcohol, cannabis, dependence, and diversion.
Every sleep medication should have a defined purpose and a plan for reassessment. A temporary prescription should not become permanent because no one revisited it.
The first weeks are part of treatment
“Monitor closely” is not enough.
The adolescent and parent should know when the next appointment will occur, what changes they should watch for, how to contact the practice, and what requires emergency care. The plan should also specify who will store the medication and what to do after missed doses.
Before changing the dose, the clinician should determine how the medication was actually taken, whether the trial was adequate, what partial benefit occurred, what adverse effects appeared, and whether something else changed: sleep, school pressure, substance use, physical illness, or family circumstances.
Persistent symptoms do not always mean the dose is too low. They may indicate poor adherence, the wrong diagnosis, an untreated coexisting condition, an environmental problem, or a medication that should be changed rather than increased.
Complicated regimens should not be continued automatically
Some adolescents arrive taking several medications prescribed over a period of years. The original reason for each one may no longer be clear.
For every medication, we ask what it was intended to treat, whether it helped, whether the target remains present, and whether one drug was added to treat the adverse effect of another.
A medication does not become necessary merely because it has been present for a long time. Continuing it is itself a prescribing decision.
Polypharmacy—treatment with several medications at the same time—can make it difficult to determine which medication is helping, which is causing an adverse effect, and whether every drug remains necessary.
Sometimes the safest next step is not another medication. It is clarifying the diagnosis, reviewing records, considering whether medication side effects are contributing to the picture, obtaining collateral information, or simplifying a regimen that has become too complicated to interpret.
Some patients need more than routine outpatient care
Rapid access does not mean that every patient can be treated safely through ordinary outpatient telehealth.
Urgent assessment, specialist consultation, or a higher level of care may be required for active suicidal intent, inability to maintain safety, suspected psychosis or mania, significant eating-disorder pathology, severe substance use, serious medical instability, repeated overdose or diversion, complex polypharmacy, or a family situation in which necessary monitoring cannot be provided.
Knowing when not to continue routine prescribing is part of prescribing well.
What changes at 18
At 18, most patients become the legal decision-makers for their care and gain control of access to their health information, subject to guardianship, incapacity, or another legally recognized authority. Parents do not automatically retain access because they have historically attended appointments or managed medication.
That transition should be discussed before the birthday. The patient needs to understand how to request refills, schedule visits, manage medication, involve family by choice, and obtain help during an emergency.
Legal responsibility changes in a day. The ability to manage treatment develops over time.
The standard surrounding the prescription
Medication can restore sleep, allow a teenager to return to school, reduce panic, loosen the hold of compulsions, or make psychotherapy possible. Careful prescribing is not reluctance to use medication when it is needed.
It means that the prescription rests on a defensible diagnosis, a defined treatment target, meaningful adolescent participation, appropriate family involvement, private communication, medication-specific monitoring, and a plan for deterioration.
The medication may fit on one line in the medical record. The work that makes it safe and effective does not.
Authorship
Erica Gettenberg, MD — Board-Certified in Adult, Child, and Adolescent Psychiatry; expertise in mood and anxiety disorders and ADHD. LinkedIn: Erica Gettenberg, MD
All vignettes are fictional and for educational purposes only. This is not a substitute for professional medical advice.
